WinstonWınston
Back
Stock

Brooks Laboratories Limited

BROOKS.NS
32
Drug Manufacturers - Specialty & Generic · Healthcare
Price
₹66.00
+1.85 (+2.88%)
Market Cap
₹1.94B
Exchange
National Stock Exchange of India
Winston Score
32
Winston is serious
Below-average fundamentals — multiple weak pillars.
Data as of Sep 6, 2026 · filings through Jun 30, 2026

§How the score breaks down

Quality
Weak
Growth
Mixed
Cash Flow
Weak
Stability
Mixed
Valuation
Good
Track this stock — start free trial

Share count rising — dilution

+18.0% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 24.9M (2022) → 29.4M (2026)

§Winston Score History

The full picture

Brooks Laboratories Limited is a pharmaceutical enterprise engaged in the contractual manufacturing and distribution of medicinal products. The company serves both the Indian domestic market and international clients. Its comprehensive product portfolio includes carbapenem medications, various tablets, dry syrups, both liquid and powdered injectable solutions, and specialized eye and ear drops. Brooks Laboratories Limited was established in 2002 and is headquartered in Mumbai, India.

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-10.0% YoY

YoY Growth Rate

Revenue declining

EPS Growth

-118.8% YoY

YoY Growth Rate

Earnings declining

R&D Spend

₹0/ year

0.0% of revenue

Below sector average (18%)

Research and development spending

Cash Position

Cash flow positive

₹0 cash & investments

Quarterly Free Cash Flow

Company generates more cash than it spends — no dilution risk from fundraising

Revenue declining

Brooks Laboratories Limited's revenue is actually shrinking. In a growth stock, that removes the core investment thesis. The low Winston Score here may be warranted — unless there's a turnaround story.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale
Gross Margin
24.6%
Thin — 24.6% gross margin
Profit after running costs
Operating Margin
6.3%
Modest — 6.3% operating margin
Return on the money invested
ROCE
3.4%
Weak — 3.4% return on capital

ROIC between 0% and 5%. They earn a few cents back per dollar invested in the business.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth
Sales YoY
-23.0%
Shrinking sales (-23.0% YoY)
Profit growth
EPS YoY
N/A
Data not available
How steady the profit is
EPS Consistency
5/8 quarters
Mixed — about half the quarters showed growth

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash
Cash Conversion
2%
Weak — only 2% of profit becomes cash
Spare cash per sale
FCF Margin
-0.5%
Burning cash (-0.5%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns
Debt / Equity
N/A
Data not available
Covers its interest
Interest Cover
5.66x
Adequate interest coverage (5.7x)

Interest coverage between 3 and 8. Profits cover interest several times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit
P/E Ratio (TTM)
14.7x
Attractive valuation — P/E 14.7

P/E in the normal range. Price is roughly $15 for every $1 of yearly profit.

Cheaper or dearer next year
P/E vs Forward
N/A
not available
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial